Physician profile
Sunshine N Murray
NPI 1184818551
$11,358.01
in general payments reported to CMS, 2019-2025
25 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $1,291 · 2021: $6,150 · 2022: $1,946 · 2023: $707 · 2024: $431 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162 · Honoraria: $150 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.85 |
| Honoraria | $150.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $7,680.09 | 2020-2024 | Axonics, Bulkamid |
| Medtronic USA, INC. | $1,455.31 | 2019-2020 | |
| Boston Scientific Corporation | $390.71 | 2019-2025 | Axonics, Advantage System, Obtryx System - Curved |
| Caldera Medical, INC | $380.38 | 2021-2024 | Desara |
| Medtronic, INC. | $362.97 | 2022 | |
| Astellas Pharma US INC | $217.45 | 2019-2022 | |
| Coloplast Corp | $204.74 | 2021-2023 | Speedicath |
| Allergan, INC. | $181.44 | 2019-2021 | |
| Abbvie INC. | $73.00 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $50.14 | 2020-2025 | Imfinzi |
| Bluewind Medical | $50.10 | 2024 | |
| Urovant Sciences INC | $48.19 | 2022 | |
| Sumitomo Pharma America, INC. | $46.17 | 2024 | Gemtesa |
| Amgen INC. | $36.34 | 2020-2021 | |
| Contura, INC. | $29.50 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $28.34 | 2022 | |
| Halozyme INC | $22.92 | 2023 | |
| Travere Therapeutics, INC. | $21.05 | 2022 | |
| Merck Sharp & Dohme LLC | $19.61 | 2021 | |
| Blue Earth Diagnostics | $17.95 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.61 | 2023 | Opdivo |
| Hollister Incorporated | $14.44 | 2022 | |
| Endo Pharmaceuticals INC. | $12.56 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,127.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunshine Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.